PUBLIC COMPANY
saveASTELLAS
USupdated 4mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Cellares and Ori Biotech’s new cell therapy manufacturing contractsPlus more from Reckitt, Astellas and Hovione. Cellares’ first Asian partnership: The manufacturer has inked a new partnership with Taiwanese company GenomeFrontier Therapeutics, under which Cellare…endpoints · 6h ago
- Sling banks $123M for an experimental thyroid eye disease pillA confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.biopharma_dive · 1d ago
- Sionna says good-bye to 46% of staffers, including execFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye diseaseInvestors are pumping $123 million into a tiny Michigan biotech that is resurrecting an Astellas cancer drug for an eye disease that has attracted lots of VC and pharma attention in recent years. S…endpoints · 1d ago
- Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trialSling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease through a phase 3 trial and hopefully on to commercialization.fiercebiotech · 2d ago
- Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according…biospace · 7d ago
- Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsNovartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbrea…biospace · 15d ago
- Mid-cap biotechs join Trump’s latest round of drug pricing dealsFocused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.biopharma_dive · 16d ago
- STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and moreNovartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug. Read the latest pharma headlines in today's…stat · 16d ago
- 9 midsize drugmakers climb aboard Trump’s MFN trainAstellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program…biospace · 16d ago
comments(0)
5-min edit window · permanent after that